Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of SLV339 in pancreatic exocrine insufficiency due to chronic pancreatitis
2007-000375-42Phase 2Completed
- Sponsor
- Solvay Pharmaceuticals
- Start
- Oct 2007
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SLV339 in exocrine pancreatic insufficiency (EPI) and chronic pancreatitis (CP), sponsored by Solvay Pharmaceuticals. Primary endpoints: Dose-response for short-term efficacy and Short-term safety of SLV339. Started Oct 2007; status: completed.
02
Drugs
SLV339
03
Conditions
exocrine pancreatic insufficiency (EPI)chronic pancreatitis (CP)
Beyond the preview
Go deeper on 2007-000375-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000375-42.